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Introduction
Pediatric neuromuscular disorders consist of different diseases 
originating from abnormality in peripheral nervous system, 
neuromuscular junction and skeletal muscle. Typically, clinical 
symptoms and signs are nonspecific and overlapping. Confirm-
ing diagnosis is not easy due to this heterogeneity, which also 
applies for the genetic perspective. Conventional diagnostic 
approach included stepwise evaluation of laboratory study, 
electrophysiologic study such as electromyography (EMG) and 
nerve conduction study (NCS) in combination with pathologic 
data obtained from muscle biopsy. Even these studies resulted 
in nonspecific diagnosis until the advance of molecular genetic 
diagnosis. As new era of genetic analysis offers therapeutic op-
tions of experimental genetically modifiable drugs and clinical 
trials, this emphasizes appropriate diagnostic approach in this 
patient population. From this context, the authors discuss char-
acteristics of pediatric neuromuscular disorders and existing 
diagnostic approaches in conjunction with new genetic diag-
nostic techniques for easier and less invasive diagnosis in these 
patients. 
Pediatric Neuromuscular Disorders
Pediatric neuromuscular disorders are a group of disorders 
manifesting hypotonia, muscle weakness and hyporeflexia, 
originating from abnormality in peripheral nervous system and 
skeletal muscle. In particular, the lesions are spread throughout 
spinal anterior horn cell, peripheral nerves, neuromuscular junc-
tion and muscular structures [1-5]. When there is abnormality 
in these regions, the patients suffer chronic progressive or non-
progressive complications resulting from abnormal muscle 
function. Skeletal muscle weakness may lead to developmental 
delay in achieving gross motor milestone, gait abnormality, and 
sometimes even to loss of independent ambulation. Depends on 
the organs involved, the patients suffer respiratory failure from 
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Clinical and genetic heterogeneity in association with overlapping spectrum is characteristic in pediatric neuromuscular disor-
ders, which makes confirmative diagnosis difficult and time consuming. Considering evolution of molecular genetic diagnosis 
and resultant upcoming genetically modifiable therapeutic options, rapid and cost-effective genetic testing should be applied 
in conjunction with existing diagnostic methods of clinical examinations, laboratory tests, electrophysiologic studies and 
pathologic studies. Earlier correct diagnosis would enable better clinical management for these patients in addition to new ge-
netic drug options and genetic counseling.
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respiratory muscle weakness, cardiomyopathy, arrhythmia and 
cardiac failure. Additionally, patients also can experience exer-
cise intolerance, myalgia and rhabdomyolysis [2,6]. 
Importance of Establishing the Right Diagnosis
Establishing the right diagnosis is important to predict prog-
nosis for the patient, and to enable anticipatory care manage-
ment for possible morbidity and multiorgan involvement [1-6]. 
Previously, most of the pediatric neuromuscular disorders were 
considered to be not curable and therefore the treatment goal 
was focused on supportive care to decrease mortality and mor-
bidity. However, with huge improvement of molecular genetic 
diagnostic methods and resultant development of genetically 
modifiable drugs, some of the patients are now offered with 
therapeutic options once their diagnosis is confirmed, especially 
with genetic testing. In addition, accurate genetic diagnosis 
would enable better genetic counseling for the patients them-
selves and their families and relatives [5-8]. 
Difficulty in Diagnostic Approach 
Nevertheless, it is hard to say that the genetic testing meth-
ods provide a one-and-only ultimate solution in diagnosing 
these children [5,7,8]. Accurate diagnosis requires complicated 
stepwise process starting from categorization according to clini-
cal symptoms and signs, followed by several studies including 
laboratory tests, electrophysiologic studies such and EMG and 
NCS, pathology and immunohistochemistry data from muscle 
biopsy, and imaging studies like ultrasound and magnetic reso-
nance imaging (MRI). Careful consideration of these informa-
tion should be given prior to genetic testing, especially due to 
cost and difficulty in interpretation of the study result [1-5]. We 
will discuss further later in the manuscript regarding pros and 
cons of genetic testing method. Even though there are certain 
disease groups in this population which have relatively notable 
clinical features such as Duchenne muscular dystrophy (DMD) 
[9], spinal muscular atrophy (SMA) [10], and Facio-scapulo-
humeral muscular dystrophy (FSHD) [1,2], most other disease 
groups generally show clinical heterogeneity which complicates 
clinical categorization [5-8]. The clinical symptoms and signs 
are not specific for each diagnosis, and phenotypically overlap-
ping. The studies currently used also complicates the diagnostic 
approach, as the results obtained from the laboratory tests, 
electrophysiologic study muscle biopsy data sometimes provide 
non-specific results, and do not indicate one particular diagno-
sis [11-14]. In addition to that, it is hard to perform these studies 
in the pediatric population due to incooperation, necessitating 
sedation with anesthesia, which will be further discussed later. 
Even genetic testing and interpretation of the results are con-
fusing that one genetic mutation may cause different diagnosis 
with overlapping clinical spectrum, while one clinical spectrum 
may be caused by multiple genetic mutations [5,7,8]. Moreover, 
even when variants of unknown significance are found with ge-
netic testing, the road to the accurate diagnosis gets even more 
complicated. For example, in patients with nemaline myopathy, 
one subtype of congenital myopathies, there are 11 genetic loci 
known to be associated with the disease [1,15,16]. In contrast, 
when there is a mutation on the ryanodine receptor (RYR1) 
gene, different pathologic features and variable clinical severity 
can be seen with this one gene mutation [17]. 
Phenotype-down Diagnostic Approach 
1. History, clinical examination and laboratory studies
To reach an accurate diagnosis, “phenotype-down” approach 
has been widely used [5]. This approach involves stepwise appli-
cation of diagnostic studies. Once again, as there are certain dis-
ease groups with characteristic clinical features, it is very impor-
tant for the clinician to make a first step of categorization with 
detailed clinical examination and history taking. Information in-
cluding prenatal and antenatal history, family history, timeline of 
motor milestone achievement and age of symptom onset needs 
to be obtained. General and neurological examinations includ-
ing inspection of facial and body dysmorphism, skin abnormali-
ties and organomegaly should also be performed. Integration of 
these information leads to prioritization of differential diagno-
ses [1,2,4,7]. As a next step, serum creatine kinase (CK) and aldol-
ase will be obtained. Serum CK level gives clue in the differential 
diagnosis and elevated serum CK usually indicates an underlying 
neuromuscular condition, especially primary muscle disorders, 
according the severity of elevation. However, serum CK can still 
be mildly elevated in neurogenic disorders as well. If serum CK 
is considerably increased up to 5-10 times compared to refer-
ence value, the clinician may suspect the diagnosis of DMD and 
Becker muscular dystrophy (BMD) spectrum [9], as well as limb-
girdle muscular dystrophy and congenital muscular dystrophy, 
which needs further evaluation [18,19]. In addition, in some 
cases when metabolic myopathies are suspected by history and 
clinical examination, the clinician can order metabolic workup 
including serum and urine studies. In metabolic myopathies, CK 
may be normal at rest and elevated after exercise, however, in 
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McArdle disease, serum CK is usually elevated. Moreover, serum 
lactate and serum lactate to pyruvate ratio is usually elevated in 
mitochondrial disorders.  
2.  Electrophysiologic studies (electromyography and 
nerve conduction study)
The next step will be either electrophysiologic studies includ-
ing EMG and NCS or pathologic study via muscle biopsy. Clini-
cian should pay careful consideration when obtaining muscle 
biopsy as it is rather invasive in nature [13,14] requiring sedation 
by anesthesia in most cases in the pediatric setting compared 
to serum studies and genetic testing available via simple blood 
draw. This is also applicable in some cases when perfoming 
needle EMG and NCS in very young children. In addition to the 
poor tolerability and difficulty in cooperation, technical difficul-
ties and interpretational challenges from lack of experienced 
pediatric electrophysiologist hinders appropriate use of these 
studies in differential diagnosis. Yet, EMG and NCS can provide 
valuable information to differentiate between neuropathy and 
myopathy [11,12], which is very helpful, especially with older 
children with ability to cooperate and for the patients with 
neuromuscular junctional problems. In myopathies, EMG shows 
low amplitude, polyphasic and short duration potentials, and in 
neurogenic disorders, NCS shows fibrillation potentials, positive 
sharp waves, fasciculation potentials and signs of reinnervation. 
In myotonic disorders, EMG shows characteristic features of 
waxing and wane myotonic discharges with particular sound. 
Yet, EMG and NCS are not easy to obtain in neonates and infants 
and not very helpful in differentiating neuropathy and myopa-
thy. This is because of need for sedation in very young children, 
and also because the reference normative values change over 
aging in these children, which requires expertise of the perform-
ing clinician [11-13]. 
In general, with the evolution of molecular genetic diagnosis, 
the need for electrophysiologic studies is decreasing [7]. Still, 
EMG and NCS will be helpful when the clinician cannot differ-
entiate further to directly go into genetic testing, such as in mo-
tor unit disorders including SMA, hereditary motor and sensory 
neuropathies, Guillain-Barre syndrome, chronic inflammatory 
demyelinating polyneuropathy and disorders of the neuromus-
cular junction [7,11]. 
3. Muscle biopsy and pathologic studies 
Muscle biopsy can be obtained if the clinician suspects the 
diagnosis of muscular dystrophy or myopathy from the infor-
mation obtained as above. Information regarding muscle histol-
ogy, histochemistry, immunohistochemistry and ultrastructure 
can be obtained. The procedure of muscle biopsy is even more 
invasive compared to the previous studies that children mostly 
needs general anesthesia. If the clinician suspects a certain 
diagnosis with easier and less invasive genetic testing, muscle 
biopsy may not be necessary, such as in DMD, SMA, and FSHD. 
However, besides these particular disease group, muscle biopsy 
still provides significant information and is essential in diagnosis 
[7]. 
By obtaining histology and histochemistry data, information 
as below can be assessed: fiber size and shape, fiber type pattern, 
position of nuclei in muscle cell, degeneration, regeneration, 
fibrosis and fatty change, cellular reaction, structural change, 
vacuole, enzyme deficiency, glycogen or lipid accumulation. 
In neurogenic condition, the muscle biopsy shows small, an-
gulated atrophied muscle fiber representing denervation, and 
fiber type grouping representing reinnervation. In myopathy, 
histology shows variety of structural defects and some are char-
acteristic in certain disease groups, and histochemistry shows 
particular enzyme defect [20,21]. In muscular dystrophy, pale-
stained or hypercontracted intensely stained degenerating 
fibers and regenerating fibers are seen, and necrosis and fibrosis 
are hallmarks of dystrophic muscles. By immunohistochemistry 
methods, one can assess absence, reduction or accumulation 
of certain proteins by labeling antibodies to specific proteins, 
which will be useful to reach a diagnosis, for example absence of 
laminin α2 suggests underlying merosin-deficient congenital 
muscular dystrophy [22]. With electron microscopy, detailed 
examination of ultrastructure and organelle of the muscle fiber 
and identification of the features seen with light microscopy 
such as vacuoles, rods, abnormal mitochondria or tubular ag-
gregates [1,7,14]. These information can give clues to reach the 
diagnosis, yet not enough to confirm genetic change, especially 
regarding genetic and pathology overlap and heterogeneity in 
these disorders, again, necessitating further process of genetic 
mutation testing by panel [1,2,5,7,8,15]. 
4. Muscle and brain imaging: ultrasound and MRI 
Recently, muscle imaging including ultrasound and MRI is 
more widely used to differentiate different forms of congenital 
myopathy by evaluating selective muscle involvement pattern. 
Previously, computed tomography scan of the muscles have also 
been utilized; however, MRI has become the gold standard cur-
rently. Ultrasound has the advantage of easy utility in clinics not 
requiring sedation. MRI of the muscles not only shows extent 
of fibrofatty changes within the muscle compartment but also 
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shows specific patterns of involvement in the muscle groups, 
like in BMD and RYR1-related myopathy. The imaging studies 
are also used to choose appropriate muscle to proceed with 
biopsy. However, the information from the imaging studies are 
variable for specificity and the interpretation is dependent on 
the expertise of the performing clinician and reading radiologist, 
and imaging study data should be considered in combination 
with other study data results including laboratory, electrophysi-
ology and pathology studies [1-3]. 
Brain MRI scan also shows significant pattern in some of the 
neuromuscular conditions in children. For example, merosin-
deficient congenital muscular dystrophy shows significant 
white matter signal changes, and in Fukuyama type of congeni-
tal muscular dystrophy and muscle-eye-brain disease, brain MRI 
shows occipital pachygyria. In Walker-Warburg syndrome, brain 
MRI shows severe lissencephaly. In mitochondrial disorders, uni-
lateral or bilateral signal change in basal ganglia is quite signifi-
cant in Leigh disease, and in mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like episodes syndrome, acute focal 
lesions which occur in relation to stroke-like episodes, but occur 
outside the usual territories of vascular infarction are common 
[1].  
New Era of Molecular Genetic Testing and Inte-
grated Diagnostic Approach
There has been a huge improvement in the technique of 
molecular genetic diagnosis in this field for the past 15 years 
[7]. Techniques including multiplex ligation-dependent probe 
amplification (MLPA) and Sanger sequencing for specific genes 
are available, as well as further advanced targeted gene panels, 
targeted next generation sequencing (NGS) or whole exome 
sequencing (WES) methods. Obtaining genetic testing has ad-
vantages in pediatric population compared to other studies that 
they are less invasive and very accurate in achieving final diag-
nosis, mode of inheritance and risk of recurrence. By achieving 
the genetic diagnosis, it is also helpful for appropriate clinical 
management to decrease morbidity and mortality, better qual-
ity of life and application of therapeutic options of genetically 
modifiable drugs and clinical trials [6-8,15]. 
In disease groups like SMA and DMD with notable clinical 
presentation and history, MLPA method to detect exon deletion 
or duplication is the first-tier test. If MLPA is negative in DMD, 
then Sanger sequencing of the dystrophin gene will be the 
second-tier test, and for other disease groups with particularly 
well-defined clinical phenotype, Sanger sequencing is the cost-
effective, less time-consuming way to detect small sequence 
variation with higher diagnostic yield [4,7,9]. However, Sanger 
sequencing can analyze only one gene at a time. As we have 
mentioned earlier, most of other neuromuscular conditions in 
childhood share overlapping clinical features originating either 
from one gene or several different genes. Considering this point, 
targeted gene panels, targeted NGS or WES methods to screen 
hundreds to thousands of genes with a single reaction is widely 
used these days [7-9,15]. 
Targeted gene panels and NGS methods have advantages of 
fast and increased throughput and coverage of regions of inter-
est. In particular for neuromuscular conditions, these methods 
can also cover genes associated with metabolic conditions as 
well as mitochondrial disorders which significantly overlap clini-
cal phenotype of myopathic features. However, they should 
be obtained with caution and should not be used as a first tier 
diagnostic test before comprehensive clinical evaluation and 
consideration of other supportive diagnostic methods. There are 
several challenges in interpreting the result from the NGS or the 
gene panel for the following reasons: firstly, clinician have to 
keep in mind that not all neuromuscular conditions in children 
are genetic diseases; secondly, there are weakness of either too 
much information vs. insufficient or unreliable information 
when interpreting the results, and this happens due to analysis 
of hundreds to thousands of genes with a single test. Some-
times, clinical may be provided with too much information of 
novel variant of unknown significance or previously unreported 
significance requiring futher functional validations. Or some-
times the results show too many polymorphisms not meeting 
clinial phenotypes which needs prioritization. On the other 
hand, sometime the results show insufficient or unreliable infor-
mation regarding repeat expansions, copy number variation, and 
some giant genes to identify a pathogenic varient. In summary, 
despite the advantages of relatively rapid and cost-effectivity in 
screening multiple genes, clinicians should put effort in choos-
ing the right panel and interpret the results with these methods. 
So far, it is reported that the diagnostic yield varies from 18-60% 
depending on the disease subtype per literature [7-9,15]. 
For cost-effective, rapid and accurate diagnosis sparing time-
consuming and invasive diagnostic tests, early referral to pediat-
ric neurologist or genetic specialist is very important. To achieve 
early referral, early detection and suspicion of neuromuscular 
disorders by clinician would be necessary. Considering that all 
infants and toddlers are to be seen by doctors on a regular ba-
sis for the national early childhood health examination under 
unified national health insurance system [23], screening of 
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developmental milestones should better be done by certified 
pediatricians for this purpose. In addition, for floppy infants 
found in neonatal intensive care unit in their neonatal period, it 
is important that the neonatologist suspect and consult to pedi-
atric neurologist or genetic specialist as early as possible [24-26]. 
In summary, when a child comes to see a pediatric neurologist 
or genetic specialist with suspicion of neuromuscular disorders, 
comprehensive diagnostic approach including detailed history 
taking, thorough clinical examination of the phenotype and 
previously used studies in combination with appropriate genetic 
testing should be done, in the most effective manner. 
Clinical Phenotype and Diagnostic Evaluations 
in the Most Common Forms of Pediatric Neuro-
muscular Disorders 
Table 1 summarizes some of the most representative disease 
groups in this population and associated diagnostic test results. 
Detailed information for each disease group will be followed, 
and these disease groups favor certain priority in the diagnostic 
approach. 
1. Spinal muscular atrophy
SMA arises from same genetic defect on chromosome 5q11-
13, mutations in the survival motor neuron 1 (SMN1) gene 
throughout the clinical spectrum of SMA0-4. Additional testing 
of SMN2 copy number is usually obtained on a research basis, 
roughly reflecting better motor function with larger number of 
SMN2 copies. The clinical spectrum divides by the age of onset 
and maximal achievable motor function, from SMA0 being the 
worst to SMA4 most mild adult form. Child neurologist usually 
see children from SMA1-3, and most of the children come to the 
clinical with hypotonia, weakness or delayed motor develop-
ment, sometimes regressing motor milestone after infection. 
The patients have depressed or absent spinal reflex and some-
times show tongue fasciculation and hand tremor. With disease 
progression, they slowly weaken and develop thoracolumbar 
scoliosis and may need surgical correction, and respiratory is-
sues might also develop necessitating ventilator support. Serum 
CK is usually mild to moderately elevated (less than 1,000 IU/L) 
but can be in normal range. With easily available genetic test-
ing of MLPA to detect deletion of exons 7 and 8 of the SMN 
gene, EMG/NCS are less performed for the diagnosis of these 
children. However, EMG/NCS shows neuropathic features and 
may support and help earlier diagnosis in very young infant 
awaiting genetic testing result. Muscle biopsy is rare obtained 
in these children, and if obtained, will show neurogenic features 
of grouped atrophy [2,4,10]. Early confirmation of diagnosis in 
these children is especially crucial as there is newly Food and 
Drug Administration (FDA) approved genetic drugs such as Spin-
raza® (nusinersen; Biogen Inc., Cambridge, MA, USA) for SMA, as 
well as upcoming clinical trials using different genetic approach 
[27-30]. 
2.  Duchenne muscular dystrophy/Becker muscular dys-
trophy
DMD and BMD are clinical spectrum originating from the dys-
trophin gene mutation, DMD being the severe form and BMD 
being the milder form. Usually, DMD results from nonsense or 
frameshift mutation of dystrophin gene which fails to produce 
functional dystrophin protein, while BMD results from the so-
called in-frame mutation which produce truncated partially 
functional dystrophin protein. DMD usually presents around age 
3 to 5 years with gross motor developmental delay and Gowers’ 
maneuver to stand up from the floor. Proximal lower extremity 
weakness is usually prominent from the presentation, and dis-
ease progression lead to loss of independent ambulation by age 
8 to 12 years without intervention. Later in the disease course, 
patients will require ventilator assistant in their teens, and car-
diac failure may follow. In comparison, BMD relatively presents 
later, generally asymptomatic during the infant and toddler ages 
and usually detected by incidental finding of elevated serum 
CK or positive family history when diagnosed during this early 
period. They present later than DMD and disease progress slower 
but in a similar manner. Serum CK is usually very high in DMD, at 
least 5 to10 times elevated from normal values and sometimes 
up to hundreds from normal values. Typical clinical feature and 
history facilitates diagnostic decision and genetic testing is 
easily available. MLPA to detect exon deletion or duplication of 
dystrophin gene is used as a first step and if negative, Sanger 
sequencing to detect point mutation is available. With easy ac-
cess of genetic testing, need for EMG/NCS and muscle biopsy 
are decreasing. If performed, EMG will show typical myopathic 
features yet it is unnecessary unless the clinical presentation is 
atypical and this is rare. Muscle biopsy might be necessary when 
MLPA is negative and the child has a positive family history and 
sequencing is not available, and the pathology will show dys-
trophic features of degenerating and regenerating fibers with 
fibrofatty replacement, and Western blot assay can quantitate 
dystrophin levels [1,2,9]. 
Despite relatively fast disease progression, it is currently con-
sidered a standard of care to treat these patients with oral glu-
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cocorticoids [31,32] as they delay disease progression, lengthen 
independent ambulation by preserving skeletal muscle and 
preserve respiratory muscle strength, decrease need for scolio-
sis surgery. In addition, there is a genetically modifiable drug 
recently approved by FDA, EXONDYS51TM (eteplirsen; Sarepta 
Therapeutics, Cambridge, MA, USA) [33-36], as well as ongoing 
and upcoming clinical trials by different approach [37]. These 
therapeutic options make it even more important to diagnose 
these children accurate and right on time. 
3. Facio-scapulo-humeral muscular dystrophy
FSHD also has a distinct clinical phenotype, and it is inher-
ited in an autosomal dominant fashion. Prominent facial and 
scapula-humeral muscle weakness and asymmetric involve-
ment is quite typical of these children, and genetic testing is 
easily available. DNA test shows an allele of decreased number 
of 1-10 residual 3.3 kb repeated DNA (D4Z4) units when in nor-
mal population, the repeat unit number varies from 10 to more 
than 100. EMG/NCS might be performed sometimes due to 
asymmetric muscle involvement which confuses clinician, and 
will show myopathic features of low amplitude, short duration 
motor unit potentials (MUP). Muscle biopsy in these children 
would show normal or nonspecific pathology, and generally not 
recommended for diagnosis [1,2,4]. 
4.  Congenital myopathy and congenital muscular  
dystro phy
These children usually presents at or slightly after birth with 
hypotonia, progressive or nonprogressive muscle weakness, 
some with respiratory and feeding problems and dysmorphic 
features. Clinical symptoms and signs are heterogenous and 
overlapping which complicates the diagnostic process. As a first 
step, serum CK will give a clue to differentiate between dystro-
phy and myopathy group that serum CK is usually much higher 
in dystrophy group, while in myopathy group serum CK is nor-
mal to mildly elevated. Even though targeted gene panel testing 
via NGS may look attractive as a shortcut, integrating other 
information including EMG/NCS, muscle biopsy and muscle and 
brain imaging would reach a final diagnosis avoiding confu-
sion interpretating complex NGS results. In both dystrophy and 
myopathy groups, EMG will show normal or myopathic features 
of low amplitude compound muscle action potentials (CMAP) 
and small polyphasic recruitment of MUPs, as well as fibrillation 
potentials. Muscle biopsy will help differentiating myopathy and 
dystrophy group and lead to specific histologic diagnosis. Spe-
cial structural change such as central nuclei, central core, multi-
minicore, nemaline rod would be seen in myopathy group while 
degenerating and regenerating fibers and fibrofatty changes 
will be seen in dystrophy group. Immunohistochemistry studies 
will further necessitate diagnosis by revealing absence or accu-
mulation of certain protein. Muscle ultrasound and MRI provide 
information regarding patterns of specific muscle involvement, 
and particular abnormality in brain MRI suggests disease such 
as Fukuyama type of congenital muscular dystrophy or Walker-
Warburg syndrome. By combining these information, final 
diagnosis can be made and when obtaining and interpretating 
NGS results, clinician should keep in mind that there are certain 
disease groups and genetic mutations unable to detect by this 
method [1,2,5,20-22]. 
5.  Myotonic dystrophy type 1 and congenital myotonic 
dystrophy
While myotonic dystrophy 1 (DM1) is one of the most com-
mon forms of muscular dystrophy in adult population, it is less 
common in children, and classified into congenital, infantile/
childhood and juvenile forms based on the age of onset and 
severity, and the clinical symptoms and signs are somewhat 
different from the classical adult DM1. However, DM1 and con-
genital DM shares genetic background the abnormal cytosine-
thiamine-guanine (CTG) trinucleotide repeat expansion in the 
myotonia dystrophia gene (DMPK), inherited in an autosomal 
dominant fashion. Classically, adult patients with DM1 shows 
clinical pattern of myotonia, muscular dystrophy, frontal bald-
ing, cataracts, cardiac conduction defects and endocrine disor-
ders. 
Clinical symptoms and signs are somewhat different in the 
congenital DM patients that they usually present with severe 
hypotonia and muscle weakness at birth, frequently accompa-
nied by respiratory and feeding difficulties, followed by intellec-
tual disability, autistic features, and abnormal musculoskeletal 
function, in general exhibiting more severe health issues. These 
babies commonly gets medical attention as floppy infants, and 
usually have previously known family history of DM or evidence 
of clinical myotonia in parental examination leads to the diag-
nosis by genetic testing. It is almost always maternally inherited. 
Anticipation is expected in these babies that with lower age of 
onset and successive generations, usually CTG repeat expan-
sion is larger (>1,500) and clinical severity increases. Yet in these 
babies, myotonia is not a prominent feature and not can be 
identified by the EMG during this period. When genetic testing 
is negative, muscle biopsy is necessary. 
Clinically the infantile and juvenile forms are more similar to 
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the adult form, yet the diagnosis is usually made later especially 
in the infantile form. Inheritance is maternal or paternal, and 
when younger, patients only exhibit mild hypotonia, lacking 
sucking and swallowing issues, nor dysmorphic features. They 
usually visit clinic with speech and learning difficulties and 
mental retardation which delays and complicates the diagnostic 
process. In these patients, the diagnosis process usually takes a 
step by step approach. In juvenile patients, clinical phenotype is 
much more similar to classical adult form with mild distal weak-
ness and delayed muscle contraction, and accompanies other 
features aforementioned in the adult form. In these patients, 
serum CK is moderately high, and NCS is normal or shows de-
creased distal CMAPs, and EMG shows myopathic features with 
typical myotonic discharges, and repetitive nerve stimulation 
test reveals decrement at 10 Hz, which leads to genetic testing 
of DMPK gene [1,2,11,38].  
6. Floppy infants 
When it comes to the floppy neonates and infants, the di-
agnostic process is even trickier and time consuming, as being 
floppy not only contains group of patients with neuromuscular 
disorders but also patients with central nervous system anoma-
lies or hypoxic brain damage and other metabolic conditions. 
So the diagnostic process would be performed step by step in a 
more conventional way. However, if the clinician suspects the 
neonates and infants to have neuromuscular condition, easy 
and less invasive genetic testing could be done. The testing 
should include SMA, congenital DM and Prader-Willi syndrome 
with one blood draw. Additional chromosomal microarray, if 
available, would be helpful in differentiating some of the most 
severe cases with relatively grave prognosis [24-26]. 
Conclusion
Diverse and nonspecific clinical symptoms and signs as well as 
overlapping genetic heterogeneity characterize pediatric neuro-
muscular disorders. For accurate and earlier diagnosis, conven-
tional diagnostic methods of laboratory, electrophysiologic and 
pathologic studies will be helpful in combination with newer 
techniques of molecular genetic testing. Accurate genetic diag-
nosis in these patients will enable better clinical management 
and therapeutic options of clinical trials and new genetically 
modifiable drug treatment.
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